$1.45
-0.07 (-4.61%)
Open$1.51
Previous Close$1.52
Day High$1.57
Day Low$1.37
52W High$3.43
52W Low$0.41
Volume—
Avg Volume523.4K
Market Cap88.58M
P/E Ratio—
EPS$-0.54
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+859.3% upside
Current
$1.45
$1.45
Target
$13.91
$13.91
$12.64
$13.91 avg
$18.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.04M | 7.06M | 6.30M |
| Net Income | 1.07M | 1.40M | 1.10M |
| Profit Margin | 15.2% | 19.8% | 17.5% |
| EBITDA | 1.93M | 2.06M | 1.69M |
| Free Cash Flow | 1.16M | 752.4K | 1.14M |
| Rev Growth | -2.7% | +19.8% | -1.2% |
| Debt/Equity | 1.45 | 1.09 | 1.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |